Immobilised Ruthenium Complexes for the Electrooxidation of 5-Hydroxymethylfurfural

Abundantly available biomass-based platform chemicals, including 5-hydroxymethylfurfural (HMF), are essential stepping stones in steering the chemical industry away from fossil fuels. The efficient catalytic oxidation of HMF to its diacid derivative, 2,5-furandicarboxylic acid (FDCA), is a promising research area with potential applications in the polymer industry. Currently, the most encouraging approaches are based on solid-state catalysts and are often conducted in basic aqueous media, conditions where HMF oxidation competes with its decomposition. Efficient molecular catalysts are practically unknown for this reaction. In this study, we report on the synthesis and electrocatalysis of surface-bound molecular ruthenium complexes for the transformation of HMF to FDCA under acidic conditions. Catalyst immobilisation on mesoporous indium tin oxide electrodes is achieved through the incorporation of phosphonic acid anchoring groups. Screening experiments with HMF and further reaction intermediates revealed the catalytic route and bottlenecks in the catalytic synthesis of FDCA. Utilising these immobilised electrocatalysts, FDCA yields of up to 85 % and faradaic efficiencies of 91 % were achieved, without any indication of substrate decomposition. Surface analysis by X-ray photoelectron spectroscopy (XPS) post-electrocatalysis unveiled the desorption of the catalyst from the electrode surface as a limiting factor in terms of catalytic performance.

Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo

BACKGROUND

Acute leukemias represent deadly malignancies that require better treatment. As a challenge, treatment is counteracted by a microenvironment protecting dormant leukemia stem cells.

METHODS

To identify responsible surface proteins, we performed deep proteome profiling on minute numbers of dormant patient-derived xenograft (PDX) leukemia stem cells isolated from mice. Candidates were functionally screened by establishing a comprehensive CRISPR‒Cas9 pipeline in PDX models in vivo.

RESULTS

A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) was identified as an essential vulnerability required for the survival and growth of different types of acute leukemias in vivo, and reconstitution assays in PDX models confirmed the relevance of its sheddase activity. Of translational importance, molecular or pharmacological targeting of ADAM10 reduced PDX leukemia burden, cell homing to the murine bone marrow and stem cell frequency, and increased leukemia response to conventional chemotherapy in vivo.

CONCLUSIONS

These findings identify ADAM10 as an attractive therapeutic target for the future treatment of acute leukemias.

In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance

Resistance towards cancer treatment represents a major clinical obstacle, preventing cure of cancer patients. To gain mechanistic insights, we developed a model for acquired resistance to chemotherapy by treating mice carrying patient derived xenografts (PDX) of acute lymphoblastic leukemia with widely-used cytotoxic drugs for 18 consecutive weeks. In two distinct PDX samples, tumors initially responded to treatment, until stable disease and eventually tumor re-growth evolved under therapy, at highly similar kinetics between replicate mice. Notably, replicate tumors developed different mutations in TP53 and individual sets of chromosomal alterations, suggesting independent parallel clonal evolution rather than selection, driven by a combination of stochastic and deterministic processes. Transcriptome and proteome showed shared dysregulations between replicate tumors providing putative targets to overcome resistance. In vivo CRISPR/Cas9 dropout screens in PDX revealed broad dependency on BCL2, BRIP1 and COPS2. Accordingly, venetoclax re-sensitized derivative tumors towards chemotherapy, despite genomic heterogeneity, demonstrating direct translatability of the approach. Hence, despite the presence of multiple resistance-associated genomic alterations, effective rescue treatment for polychemotherapy-resistant tumors can be identified using functional testing in preclinical models.